Omega Therapeutics, Inc. (OMGA): Price and Financial Metrics
OMGA Price/Volume Stats
| Current price | $4.29 | 52-week high | $10.09 |
| Prev. close | $4.25 | 52-week low | $1.30 |
| Day low | $4.01 | Volume | 747,600 |
| Day high | $4.30 | Avg. volume | 3,798,206 |
| 50-day MA | $3.43 | Dividend yield | N/A |
| 200-day MA | $4.15 | Market Cap | 236.56M |
OMGA Stock Price Chart Interactive Chart >
OMGA POWR Grades
- Sentiment is the dimension where OMGA ranks best; there it ranks ahead of 89.79% of US stocks.
- OMGA's strongest trending metric is Growth; it's been moving up over the last 26 weeks.
- OMGA ranks lowest in Quality; there it ranks in the 9th percentile.
OMGA Stock Summary
- OMGA's price/sales ratio is 52.99; that's higher than the P/S ratio of 96.74% of US stocks.
- With a year-over-year growth in debt of 473.22%, OMEGA THERAPEUTICS INC's debt growth rate surpasses 97.96% of about US stocks.
- Revenue growth over the past 12 months for OMEGA THERAPEUTICS INC comes in at 91.57%, a number that bests 95.08% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to OMEGA THERAPEUTICS INC, a group of peers worth examining would be PULM, QURE, INDI, HOWL, and CARA.
- To check out OMEGA THERAPEUTICS INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001850838.
OMGA Valuation Summary
- OMGA's price/earnings ratio is -1.5; this is 105.15% lower than that of the median Healthcare stock.
- Over the past 29 months, OMGA's EV/EBIT ratio has gone up 19.8.
Below are key valuation metrics over time for OMGA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| OMGA | 2023-12-29 | 58.4 | 2.2 | -1.5 | -1.9 |
| OMGA | 2023-12-28 | 60.2 | 2.2 | -1.6 | -2.0 |
| OMGA | 2023-12-27 | 62.3 | 2.3 | -1.6 | -2.0 |
| OMGA | 2023-12-26 | 59.6 | 2.2 | -1.6 | -2.0 |
| OMGA | 2023-12-22 | 47.9 | 1.8 | -1.3 | -1.7 |
| OMGA | 2023-12-21 | 46.6 | 1.7 | -1.2 | -1.6 |
Omega Therapeutics, Inc. (OMGA) Company Bio
Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer. It is also developing OTX-2002 to down-regulate c-Myc, an oncogene. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Latest OMGA News From Around the Web
Below are the latest news stories about OMEGA THERAPEUTICS INC that investors may wish to consider to help them evaluate OMGA as an investment opportunity.
Omega Therapeutics to Participate in the H.C. Wainwright 4th Annual Precision Oncology Virtual ConferenceCAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in a fireside chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference on Wednesday, December 6, 2023, at 9:30 a.m. ET. A live webcast of the fireside chat will be available on the Investors & Media secti |
Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of GeneticsFlagship Pioneering, the bioplatform innovation company, today unveiled Quotient Therapeutics, a company pioneering somatic genomics, the study of genetic variation at the cellular level, to discover therapeutics informed by new links between genes and disease. Flagship has made an initial commitment of $50 million to advance development of the company's platform following two years of development at Flagship Labs and pursue a pipeline of medicines across a wide range of therapeutic areas and mo |
Omega Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare ConferenceCAMBRIDGE, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023, at 12:00 p.m. ET. A live webcast of the fireside chat will be available on the Investors & Media section of the Compa |
Omega Therapeutics Showcases Bidirectional and Multiplexed Epigenomic Control of Gene Expression in Preclinical Models of Liver Inflammation and FibrosisFirst-ever demonstration of sustained pre-transcriptional upregulation of gene expression by an epigenomic controller in both in vitro and in vivo models of liver fibrosis Single epigenomic controller demonstrated ability to simultaneously regulate the expression of chemokines CXCL9-11 across in vitro models of liver inflammation CAMBRIDGE, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development |
Omega Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Company ProgressAnnounced promising preliminary clinical data for OTX-2002 from ongoing MYCHELANGELO™ I trial; clinical proof-of-platform established with potential applicability across a broad range of diseasesAdvanced OMEGA platform capabilities and presented new preclinical data on multiple epigenomic controller programs at medical meetingsFurther strengthened Board of Directors with appointment of Chris Schade as Chairman and addition of Michelle C. Werner CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- |
OMGA Price Returns
| 1-mo | 27.30% |
| 3-mo | 124.61% |
| 6-mo | 14.71% |
| 1-year | -29.67% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 42.52% |
| 2023 | -47.29% |
| 2022 | -49.60% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...